颖泰生物
(920819)
| 流通市值：32.35亿 | | | 总市值：32.73亿 |
| 流通股本：12.12亿 | | | 总股本：12.26亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 3,901,373,190.99 | 2,763,626,143.04 | 1,355,490,197.14 | 5,474,030,024.74 |
| 营业总成本 | 3,906,802,670.8 | 2,736,385,354.36 | 1,364,489,867.01 | 5,533,691,285.33 |
| 其他经营收益 | | | | |
| 营业利润 | -29,001,262.53 | 42,240,421.78 | -4,069,207.47 | -208,472,492.75 |
| 利润总额 | -31,818,802.67 | 40,332,913.29 | -3,997,311.43 | -215,562,809.15 |
| 净利润 | -74,678,312.05 | 3,899,489.49 | -20,594,018.38 | -260,398,538.1 |
| 每股收益 | | | | |
| 其他综合收益 | -52,551,036.66 | -36,504,279.67 | -13,752,449.56 | -3,197,989.92 |
| 综合收益总额 | -127,229,348.71 | -32,604,790.18 | -34,346,467.94 | -263,596,528.02 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 3,881,230,076.16 | 4,108,191,419.36 | 4,032,768,976.7 | 4,332,279,849.6 |
| 非流动资产: | | | | |
| 非流动资产合计 | 6,824,527,129.91 | 6,936,725,330.83 | 7,010,969,371.68 | 7,062,932,346.36 |
| 资产总计 | 10,705,757,206.07 | 11,044,916,750.19 | 11,043,738,348.38 | 11,395,212,195.96 |
| 流动负债: | | | | |
| 流动负债合计 | 5,028,780,849.67 | 5,166,980,222.13 | 5,194,075,297.63 | 5,576,765,128.21 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,039,472,162.77 | 1,143,216,443.77 | 1,112,009,896.94 | 1,049,722,264.35 |
| 负债合计 | 6,068,253,012.44 | 6,310,196,665.9 | 6,306,085,194.57 | 6,626,487,392.56 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,664,634,143.12 | 4,759,425,651.44 | 4,754,249,351.15 | 4,784,555,662.86 |
| 股东权益合计 | 4,637,504,193.63 | 4,734,720,084.29 | 4,737,653,153.81 | 4,768,724,803.4 |
| 负债和股东权益合计 | 10,705,757,206.07 | 11,044,916,750.19 | 11,043,738,348.38 | 11,395,212,195.96 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 3,192,000,412.17 | 2,096,583,064.27 | 1,196,309,548.6 | 4,440,845,274.3 |
| 经营活动现金流出小计 | 2,748,477,295.09 | 1,925,417,226 | 1,093,294,869.99 | 3,841,856,825.1 |
| 经营活动产生的现金流量净额 | 443,523,117.08 | 171,165,838.27 | 103,014,678.61 | 598,988,449.2 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 133,598,915.26 | 124,995,285.88 | 70,451,222.4 | 176,146,602.2 |
| 投资活动现金流出小计 | 95,605,000.57 | 76,482,699.4 | 54,503,775.93 | 262,811,525.74 |
| 投资活动产生的现金流量净额 | 37,993,914.69 | 48,512,586.48 | 15,947,446.47 | -86,664,923.54 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 2,673,678,085.98 | 1,517,367,576.31 | 728,329,787.82 | 4,679,325,220.07 |
| 筹资活动现金流出小计 | 3,218,182,960.02 | 1,765,617,042.47 | 840,793,502.05 | 5,105,230,087.74 |
| 筹资活动产生的现金流量净额 | -544,504,874.04 | -248,249,466.16 | -112,463,714.23 | -425,904,867.67 |
| 汇率变动对现金及现金等价物的影响 | -19,383,767.82 | -11,018,685.01 | -5,104,944.28 | 6,196,484.86 |
| 现金及现金等价物净增加额 | -82,371,610.09 | -39,589,726.42 | 1,393,466.57 | 92,615,142.85 |
| 期末现金及现金等价物余额 | 539,100,448.77 | 581,882,332.44 | 622,865,525.43 | 621,472,058.86 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -39,589,726.42 | - | 92,615,142.85 |